Alemtuzumab is a humanized recombinant IgG1κ fragment which binds to CD52 on the surface of malignant and normal T & B lymphocytes, NK cells, monocytes and macrophages. Alemtuzumab's proposed mechanism of action is antibody dependent lysis of leukemic cells. It's primary indication is in the treatment of chronic B-lymphocyte leukemia in patients who have failed alkylating agent and fludarabine therapy.
| Source | Link | Revision Date | Access Date |
| Campath | http://www.campath.com/hcp/index.jsp | 2007-September | 2008-May-30 |
NO RELIANCE FOR MEDICAL DECISIONSInformation, services and/or other features contained in this web site (including any electronic bulletin board contained therein) are being provided for general educational and informational purposes only and are not intended to be a substitute for independent medical judgment or constitute case-specific medical advice or treatment in any way. Such information, services and/or features are not intended to serve as the primary basis for making personal or professional medical decisions, nor are they intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to making any treatment or diagnosis decisions and with any questions you may have regarding a medical condition or its diagnosis or treatment. You should confirm any information obtained from this site with other sources before undertaking any treatment or otherwise taking any actions relating thereto. Any reliance on any information, services or other features contained in this site is solely at your own risk. |
|
Clinical Immunology Society 555 East Wells Street, Suite 1100 Milwaukee, WI 53202-3823 USA Phone: 414/224-8095 | Fax: 414/272-6070 Email: info@clinimmsoc.org © 2001-2008 Clinical Immunology Society | Web Site Disclaimer |
